Your session is about to expire
← Back to Search
Cabozantinib + Temozolomide for Soft Tissue Sarcoma
Study Summary
This trial is studying how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 45 Patients • NCT02101736Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organ and bone marrow functions are within normal ranges.I am using birth control or my partner is.My brain cancer has not worsened after treatment.I don't have another cancer that could affect this treatment's safety or results.I have not had major surgery in the last 56 days.I am not pregnant and can become pregnant.I haven't had any radionuclide treatment in the last 42 days.I have had up to 5 chemotherapy treatments for my recurrent or spreading cancer.I have taken certain medications recently.I have recovered from side effects of previous treatments to my normal health or have only mild side effects.I understand the study requirements and have signed the consent form.My diagnosis is an inoperable or metastatic leiomyosarcoma or another type of soft tissue sarcoma.I am fully active or restricted in physically strenuous activity but can do light work.I cannot swallow pills.I have previously been treated with cabozantinib or temozolomide.I am currently taking blood thinners.I do not have any severe ongoing illnesses like heart or stomach problems.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Treatment (cabozantinib, temozolomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many patients are included in this clinical trial?
"Yes, the trial is recruiting patients. According to the listings on clinicaltrials.gov, the study was first advertised on 1/14/2020 and was last updated on 7/11/2022. They are hoping to enroll 72 people at 5 different medical sites."
What other clinical trials are there that focus on Cabozantinib?
"577 clinical trials have been completed for cabozantinib since its inception in 2002 at the Memorial Sloan Kettering Cancer Center. Out of these, 332 are actively recruiting patients with many of the studies based in Chicago, Illinois."
Has research like this been conducted before?
"Since its inception in 2002, there have been a total of 332 clinical trials researching cabozantinib in 50 different countries. The very first study was sponsored by Schering-Plough and took place in 2002, involving only 60 patients. However, after the successful completion of the Phase 2 drug trial, cabozantinib received approval for heavier use. Currently, there are 1567 cities across the globe with active studies underway."
Is Cabozantinib dangerous at the therapeutic dose?
"Given that this is a Phase 2 trial, where there is some preliminary data supporting safety but not yet efficacy, our team has rated the safety of Cabozantinib as a 2."
Are there any current openings for candidates in this clinical trial?
"This clinical trial, which is currently recruiting patients, was originally posted on January 14th 2020. The listing was most recently updated on July 11th 2022."
What are the most common conditions that Cabozantinib is used to address?
"Cabozantinib is often used to treat patients who have undergone anti-vegf treatment. This medication can also be helpful for those receiving nitrosourea therapy, as well as high risk patients."
Share this study with friends
Copy Link
Messenger